07:16 AM EST, 12/16/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said late Friday that the US Food and Drug Administration has approved its drug, Crenessity, as an adjunctive treatment to glucocorticoid replacement for controlling androgens in adults and pediatric patients with classic congenital adrenal hyperplasia.

The company said the drug is expected to be commercially available in about a week.

The Food and Drug Administration approval is based on phase 3 studies that showed Crenessity significantly reduced androstenedione levels compared to placebo.